Sex: U
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Moderate injection site redness; Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch); Mild injection site swelling; Moderate fever (101.3 to 102 °F); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Moderate fever (101.3 to 102 °F).         No concomitant medications were reported. It was reported that the patient had experienced Moderate injection site pain interfering with activity, Mild injection site tenderness (tender to touch), Moderate injection site redness, Mild injection site swelling, Moderate fever, Mild fatigue and no interference with activity, Mild malaise/feeling sick and no interference with activity, Mild muscle pain and no interference with activity, anytime during the 2 days after your COVID-19 vaccination, which occurred on Tuesday, 19-Dec-2023 and Wednesday, 20-Dec-2023. No treatment medications were reported.  The RTI-HS Subject ID was reported. the AutoCruitment Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099: